<div id="readability-page-1"><div>We are truly in a new era. We have opened the door to understanding and manipulating the biology of Alzheimer's disease for the benefit of our patients,&#34; NEWARK, DE / ACCESS Newswire / February 12, 2026 / The global Alzheimer's therapeutics market is entering a historic transformation phase. Valued at USD 4.3 billion in 2026, the market is projected to more than double to USD 10.4 billion by 2036, expanding at a robust CAGR of 9.3%. This growth is being fueled by a paradigm shift from purely symptomatic management toward disease-modifying immunotherapies that directly target the biological drivers of Alzheimer's disease.According to a comprehensive strategic outlook from Future Market Insights (FMI), recent FDA approvals of anti-amyloid therapies such as lecanemab and donanemab have fundamentally reshaped the clinical landscape, marking the first credible pathway to slowing disease progression rather than simply managing cognitive decline. This shift is unlocking a new era of therapeutic innovation, infrastructure investment, and value-based care models across global healthcare systems. <img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/imagelibrary/11755059-8e0c-4a27-98f0-044c67fef8a0/1136691/alzheimers-therapeutics-market.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1344" height="768" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/imagelibrary/11755059-8e0c-4a27-98f0-044c67fef8a0/1136691/alzheimers-therapeutics-market.png"/> From Symptom Control to Disease Modification: A Structural ShiftThe industry is undergoing a structural realignment as traditional cholinesterase inhibitors, led by Donepezil, continue to dominate treatment volume, while high-cost biologics drive disproportionate value growth. FMI identifies this as a &#34;dual-engine market,&#34; where legacy oral therapies ensure broad patient coverage, while infusion-based immunotherapies redefine revenue dynamics.&#34;We are truly in a new era. We have opened the door to understanding and manipulating the biology of Alzheimer's disease for the benefit of our patients,&#34; notes Jeff Cummings, Professor of Brain Science, University of Nevada.This evolution is accelerating investments in diagnostic screening, biomarker testing, and infusion center capacity, as healthcare systems prepare to support a new standard of care centered on early intervention and biologic administration.Infrastructure and Economics: Hospitals Become the Central HubThe rise of infusion-based therapies is shifting distribution power toward hospital pharmacies, which now command 35.0% of total market share. These facilities are uniquely equipped to manage complex biologics, MRI monitoring, and safety protocols for adverse effects such as ARIA (Amyloid-Related Imaging Abnormalities).The economic burden of Alzheimer's disease is further intensifying this shift. In the United States alone, total dementia care costs are projected to reach USD 384 billion in 2025, with Medicare and Medicaid accounting for USD 246 billion. As payers demand stronger health-economic evidence, pharmaceutical companies must now demonstrate not only clinical efficacy, but also the ability to reduce long-term institutionalization and overall system costs.Segment Spotlight: Donepezil and the Rise of Biologics<ul><li>Donepezil (67.7% Share): Retains dominance due to low cost, oral availability, and first-line status across all disease stages, ensuring continued relevance for symptom management.</li><li>Amyloid Immunotherapies: While lower in volume, these therapies are driving the majority of value growth, reshaping pricing, reimbursement, and care delivery models.</li><li>Hospital Pharmacies (35.0% Share): Strengthening their leadership as the primary channel for high-value, infusion-based treatments.</li></ul>Regional Powerhouses: Asia and Emerging Markets AccelerateWhile North America and Europe remain high-value markets, the fastest growth is occurring in Asia, where aging populations and evolving healthcare infrastructure are rapidly expanding access:<ul><li>Japan (12% CAGR): A super-aged society and supportive regulatory environment are positioning Japan as a global testbed for advanced Alzheimer's care.</li><li>India (11.6% CAGR): Growth is driven by expanding hospital networks, rising awareness, and demand for scalable, cost-effective therapies.</li><li>United States (9% CAGR): A mature but dynamic market where innovation is colliding with reimbursement reform and massive patient volumes.</li></ul>Market Metrics at a Glance (2026-2036)<table><thead><tr><th>Market Metric</th><th>Value / Detail</th></tr></thead><tbody><tr><td>Current Market Value (2026)</td><td>USD 4.3 Billion</td></tr><tr><td>Projected Market Value (2036)</td><td>USD 10.4 Billion</td></tr><tr><td>Global Growth Rate (CAGR)</td><td>9.3%</td></tr><tr><td>Leading Drug</td><td>Donepezil (67.7%)</td></tr><tr><td>Leading Distribution Channel</td><td>Hospital Pharmacies (35.0%)</td></tr><tr><td>Top Growth Markets</td><td>Japan (12%), India (11.6%)</td></tr></tbody></table>Dynamics of the Decade: Biomarkers, Multi-Mechanism Therapies, and Value-Based CareLooking ahead to 2036, FMI identifies several forces set to redefine competitive advantage:<ul><li>Blood-Based Diagnostic Revolution: Highly accurate blood biomarker tests (85-90% accuracy) are democratizing early diagnosis and expanding the pool of treatable patients.</li><li>Multi-Mechanism Synergies: Combination therapies targeting amyloid, tau, inflammation, and metabolic dysfunction are emerging as the next frontier.</li><li>Value-Driven Reimbursement: Payers are increasingly linking reimbursement to demonstrated reductions in long-term care costs and institutionalization rates.</li></ul>&#34;But just over the last five or so years, we've hit an inflection point. We're starting to get traction,&#34; says Martin Kampmann, Professor at UCSF, highlighting the momentum behind next-generation Alzheimer's therapies.Competitive LandscapeThe market is defined by an intensifying race to dominate the disease-modifying segment while defending legacy symptomatic franchises. Tier-1 pharmaceutical players are increasing R&amp;D reinvestment, often allocating 20-25% of revenue to neurodegenerative pipelines, while M&amp;A activity accelerates to secure novel mechanisms of action.Key Players in the Alzheimer's Therapeutics Market: Eisai Co. Ltd., Novartis AG, AbbVie, Biogen, Eli Lilly and Company, Aurobindo Pharma Ltd., Johnson &amp; Johnson, Dr. Reddy's Laboratories Ltd., Viatris, F. Hoffmann-La Roche Ltd.For an in-depth analysis of evolving therapeutic strategies, biomarker integration, and regional growth opportunities, access the complete strategic outlook for the Alzheimer's Therapeutics Market through 2036 at: https://www.futuremarketinsights.com/reports/alzheimers-therapeutics-marketRelated Reports:<ul><li>COPD Therapeutics Market: https://www.futuremarketinsights.com/reports/chronic-obstructive-pulmonary-disease-therapeutics-market</li><li>Digital Therapeutics Market: https://www.futuremarketinsights.com/reports/digital-therapeutics-market</li><li>Peptide Therapeutics Market: https://www.futuremarketinsights.com/reports/peptide-therapeutics-market</li><li>Glaucoma Therapeutics Market: https://www.futuremarketinsights.com/reports/glaucoma-therapeutics-market</li><li>Pet Cancer Therapeutics Market: https://www.futuremarketinsights.com/reports/pet-cancer-therapeutics-market</li></ul>About Future Market Insights (FMI)Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Headquartered in Delaware, USA, with a global delivery center in India and offices in the UK and UAE, FMI delivers actionable insights to businesses across industries including automotive, technology, healthcare, consumer products, manufacturing, energy, and chemicals.An ESOMAR-certified research organization, FMI provides custom and syndicated market reports and consulting services, supporting both Fortune 1,000 companies and SMEs. Its team of 300+ experienced analysts ensures credible, data-driven insights to help clients navigate global markets and identify growth opportunities.For Press &amp; Corporate Inquiries Rahul Singh AVP - Marketing and Growth Strategy Future Market Insights, Inc. +91 8600020075 For Sales - sales@futuremarketinsights.com For Media - Rahul.singh@futuremarketinsights.com For web - https://www.futuremarketinsights.comSOURCE: Future Market Insights, Inc.View the original press release on ACCESS Newswire <img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzNjY5MQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzNjY5MQ"/></div></div>

全球阿爾茨海默病治療市場預計將從 2026 年的 43 億美元增長到 2036 年的 104 億美元，年均增長率為 9.3%。這一增長主要受到向疾病修飾性免疫療法轉變的推動，例如抗澱粉樣蛋白療法，旨在減緩疾病進展。醫院藥房在分銷中變得越來越重要，佔據 35% 的市場份額。主要增長市場包括日本和印度，而多奈哌齊仍然是領先藥物。隨着製藥公司增加研發投資，市場正在隨着診斷技術和多機制療法的進步而不斷演變

由於疾病修飾性免疫療法正在改變治療範式，阿爾茨海默症治療市場預計到 2036 年將達到 104 億美元